Fostamatinib Disodium / R935788

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Purpura, Thrombocytopenic, Idiopathic

Drug Information

Target Indication

Purpura, Thrombocytopenic, Idiopathic

Clinical Trial

Last updated: 2/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA1/9/2020

Tavlesse

Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.

Drug Science

Mechanism of action & safety profile

Developer

RIGL

RIGEL PHARMACEUTICALS INC

Related Pipeline

Immune Thrombocytopenic Purpura

Lymphoma

Warm Antibody Autoimmune Hemolytic Anemia

Rheumatoid Arthritis

IGA Nephropathy

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts